Clinically,
COVID-19 is often accompanied by a severe immune response (
cytokine storm) which produces a large number of
cytokines, such as TNF-α,
IL-6 and
IL-12, and consequently causes
acute respiratory distress syndrome (ARDS). GMI is a type of fungal immunomodulatory
protein that is cloned from Ganoderma microsporum and acts as modulating immunocyte for various inflammatory diseases. This study identifies GMI as a potential
anti-inflammatory agent and determines the effects of GMI on the inhibition of SARS-CoV-2-induced
cytokine secretion. Functional studies showed that SARS-CoV-2 envelope (E)
protein induces inflammatory process in murine macrophages RAW264.7 and MH-S cells and in
phorbol 12-myristate 13-acetate (PMA)-stimulated human THP-1 cells. GMI exhibits a strong inhibitory effect for SARS-CoV-2-E-induced pro-inflammatory mediators, including NO, TNF-α,
IL-6, and
IL-12 in macrophages. GMI reduces SARS-CoV-2-E-induced intracellular inflammatory molecules, such as iNOS and COX-2, and inhibits SARS-CoV-2-E-stimulated phosphorylation of ERK1/2 and P38. GMI also downregulates pro-inflammatory
cytokine levels in lung tissue and serum after the mice inhale SARS-CoV-2-E
protein. In conclusion, this study shows that GMI acts as an agent to alleviate SARS-CoV-2-E-induced
inflammation.